COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS AFFECTED BY CHRONIC KIDNEY DISEASE IN ITALY

被引：0
|
作者：
Di Costanzo, A. [1 ]
Uster, A. [2 ]
Vassallo, C. [1 ]
Fiorentino, F. [1 ]
机构：
[1] IQVIA Solut Srl, Milan, Italy
[2] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE117
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN ADULT PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE NETHERLANDS
    Fens, T.
    Weersma, M.
    Postma, M. J.
    Boersma, C.
    de Jong, L.
    VALUE IN HEALTH, 2023, 26 (12) : S132 - S132
  • [2] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE (CKD) MANAGEMENT IN THE UK
    Ramos, M.
    Gerlier, L.
    Uster, A.
    Aguirre, A. R.
    Muttram, L.
    Frankel, A. H.
    Lamotte, M.
    VALUE IN HEALTH, 2023, 26 (12) : S131 - S132
  • [3] Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial
    Harinala Groyer
    Romain Supiot
    Jean Tardu
    Nicolas Virely
    Marine Sivignon
    Denis San
    Pierre Lévy
    Anastasia Ustyugova
    Ziad A. Massy
    Clinical Drug Investigation, 2024, 44 (11) : 811 - 828
  • [4] Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom
    Ramos, Mafalda
    Gerlier, Laetitia
    Uster, Anastasia
    Muttram, Louise
    Frankel, Andrew H.
    Lamotte, Mark
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 777 - 785
  • [5] Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy
    Mannucci, Edoardo
    Ghetti, Gianni
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2022, 23 (01) : 85 - 95
  • [6] Time to Invest in the Future: Assessing the Cost-Effectiveness of Empagliflozin in Diabetic Kidney Disease
    Khine, Annika
    Kwok, Jonas
    Lin, Eugene
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (06) : 780 - 782
  • [7] Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan
    Kodera, Satoshi
    Morita, Hiroyuki
    Nishi, Hiroshi
    Takeda, Norifumi
    Ando, Jiro
    Komuro, Issei
    CIRCULATION JOURNAL, 2022, 86 (12) : 2021 - +
  • [8] Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease
    Klarenbach, SW
    Pannu, N
    Tonelli, MA
    Manns, BJ
    CRITICAL CARE MEDICINE, 2006, 34 (04) : 1044 - 1051
  • [9] The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease
    Yarnoff, Benjamin O.
    Hoerger, Thomas J.
    Simpson, Siobhan A.
    Pavkov, Meda E.
    Burrows, Nilka R.
    Shrestha, Sundar S.
    Williams, Desmond E.
    Zhuo, Xiaohui
    PLOS ONE, 2016, 11 (07):
  • [10] A REVIEW OF COST-EFFECTIVENESS ANALYSES FOR ANEMIA IN CHRONIC KIDNEY DISEASE
    Lavelle, Tara
    Michalopoulos, Steven
    Margaretos, Nikki
    Berklein, Flora
    Shafai, Gigi
    Bozas, Ana
    Sanon, Myrlene
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (05) : 707 - 707
12345